| Literature DB >> 26056428 |
Asima Bajwa1, Diba Osmanzada1, Susan Osmanzada1, Irfan Khan1, Jim Patrie2, Wenjun Xin2, Ashvini K Reddy1.
Abstract
PURPOSE: To demonstrate the demographic, anatomic, and diagnostic classification of patients with uveitis seen in a tertiary care center in central Virginia.Entities:
Keywords: central Virginia; demographics; mid-Atlantic United States
Year: 2015 PMID: 26056428 PMCID: PMC4445955 DOI: 10.2147/OPTH.S80972
Source DB: PubMed Journal: Clin Ophthalmol ISSN: 1177-5467
Figure 1Map showing centers of the US-based epidemiological studies (created in Microsoft MapPoint® 2013; Microsoft Corp, Redmond, WA, USA).
Note: The red dots indicate center locations.
Figure 2Mean age at diagnosis and presentation.
Note: Intervals are non-overlapping. Each interval is open on the left and closed on the right (eg, [0, 10 years]).
Age groups
| Age group (years) | Patients, n | Percentage |
|---|---|---|
| <18 | 39 | 7.9 |
| 18–35 | 129 | 26.3 |
| 18–65 | 355 | 72.3 |
| >65 | 97 | 19.8 |
Notes:
The groups were defined as: <18 years = pediatric group; 18–35 years = young adults; 18–65 years = working-age group; >65 years = older-age group.
Distribution of diagnoses by sex
| Diagnosis | Female | Male | |
|---|---|---|---|
| Anterior uveitis, undifferentiated | 73 (26.3) | 53 (24.9) | 0.755 |
| Trauma | 40 (14.3) | 20 (9.4) | 0.098 |
| Viral | |||
| Herpetic anterior uveitis | 30 (10.8) | 9 (4.2) | 0.011 |
| Acute retinal necrosis | 9 (3.2) | 4 (1.9) | 0.408 |
| CMV uveitis | 2 (0.7) | 2 (0.9) | 1.000 |
| Herpetic panuveitis | 1 (0.4) | 0 (0.0) | 1.000 |
| Post-procedural uveitis | 21 (7.6) | 28 (13.1) | 0.048 |
| Anterior uveitis HLA-B27 | 18 (6.5) | 15 (7.0) | 0.857 |
| Sarcoidosis | 17 (6.1) | 16 (7.5) | 0.588 |
| Intermediate uveitis | 11 (4.0) | 8 (3.8) | 1.000 |
| Panuveitis, undifferentiated | 11 (4.0) | 12 (5.6) | 0.397 |
| Others | 8 (2.9) | 11 (5.2) | 0.240 |
| Infectious, nonviral | |||
| Toxoplasma | 8 (2.9) | 6 (2.8) | 1.000 |
| Fungal | 3 (1.1) | 1 (0.5) | 0.637 |
| Syphilis | 1 (0.4) | 0 (0.0) | 1.000 |
| Tuberculosis | 1 (0.4) | 0 (0.0) | 1.000 |
| Posterior uveitis, undifferentiated | 6 (2.2) | 3 (1.4) | 0.738 |
| White dot syndrome | |||
| Birdshot | 5 (1.8) | 2 (0.9) | 0.704 |
| MEWDS | 2 (0.7) | 1 (0.5) | 1.000 |
| Multifocal choroiditis | 1 (0.4) | 8 (3.8) | 0.012 |
| APMPPE | 1 (0.4) | 3 (1.4) | 0.321 |
| Serpiginous | 1 (0.4) | 2 (0.9) | 0.582 |
| Seronegative SpA | |||
| Ankylosing spondylitis | 2 (0.7) | 3 (1.4) | 0.657 |
| Crohn’s disease | 2 (0.7) | 2 (0.9) | 1.000 |
| Ulcerative colitis | 1 (0.4) | 1 (0.5) | 1.000 |
| Reactive arthritis | 1 (0.4) | 0 (0.0) | 1.000 |
| Psoriatic arthritis | 0 (0.0) | 1 (0.5) | 0.434 |
| Eales disease | 1 (0.4) | 0 (0.0) | 1.000 |
| Collagen vascular disease | |||
| Polyarteritis nodosa | 1 (0.4) | 0 (0.0) | 1.000 |
| Granulomatosis with polyangiitis | 0 (0.0) | 1 (0.5) | 0.434 |
| Total | 279 (100.0) | 214 (100.0) | 0.066 |
Notes:
Fisher’s exact test on 2×2 table, eg, female vs male compared on sarcoidosis vs all other diagnoses.
Fisher’s exact test applied to entire table, using Monte Carlo sampling (P=0.085).
Abbreviations: APMPPE, acute posterior multifocal placoid pigment epitheliopathy; CMV, cytomegalovirus; HLA, human leukocyte antigen; MEWDS, multiple evanescent white dot syndrome; seronegative SpA, seronegative spondyloarthropathy.
Distribution of diagnoses by race
| Diagnosis | African American | Caucasian | |
|---|---|---|---|
| Viral | |||
| Herpetic anterior uveitis | 2 (1.5) | 32 (10.8) | <0.001 |
| Acute retinal necrosis | 5 (3.7) | 8 (2.7) | 0.553 |
| CMV uveitis | 1 (0.7) | 3 (1.0) | 1.000 |
| Herpetic panuveitis | 0 (0.0) | 1 (0.3) | 1.000 |
| Sarcoidosis | 23 (17.2) | 9 (3.0) | <0.001 |
| Anterior uveitis, undifferentiated | 40 (29.9) | 63 (21.2) | 0.067 |
| Trauma | 22 (16.4) | 35 (11.8) | 0.219 |
| Post-procedural | 14 (10.4) | 27 (9.1) | 0.723 |
| Anterior uveitis HLA-B27 | 8 (6.0) | 22 (7.4) | 0.686 |
| Others | 2 (1.5) | 15 (5.1) | 0.108 |
| Intermediate uveitis | 3 (2.2) | 14 (4.7) | 0.291 |
| Panuveitis, undifferentiated | 7 (5.2) | 13 (4.4) | 0.805 |
| Infectious (bacterial, fungal, parasitic) | |||
| Toxoplasma | 1 (0.7) | 10 (3.4) | 0.185 |
| Fungal | 0 (0.0) | 4 (1.3) | 0.315 |
| Syphilis | 0 (0.0) | 1 (0.3) | 1.000 |
| Tuberculosis | 0 (0.0) | 0 (0.0) | 1.000 |
| Posterior uveitis, undifferentiated | 2 (1.5) | 6 (2.0) | 1.000 |
| White dot syndrome | |||
| Multifocal choroiditis | 3 (2.2) | 5 (1.7) | 0.708 |
| Birdshot | 0 (0.0) | 5 (1.7) | 0.330 |
| APMPPE | 0 (0.0) | 4 (1.3) | 0.315 |
| Serpiginous | 0 (0.0) | 3 (1.0) | 0.556 |
| MEWDS | 0 (0.0) | 2 (0.7) | 1.000 |
| Seronegative SpA | |||
| Ankylosing spondylitis | 0 (0.0) | 5 (1.7) | 0.330 |
| Crohn’s disease | 0 (0.0) | 4 (1.3) | 0.315 |
| Reactive arthritis | 0 (0.0) | 1 (0.3) | 1.000 |
| Ulcerative colitis | 0 (0.0) | 1 (0.3) | 1.000 |
| Psoriatic arthritis | 0 (0.0) | 1 (0.3) | 1.000 |
| Collagen vascular disease | |||
| Granulomatosis with polyangiitis | 0 (0.0) | 1 (0.3) | 1.000 |
| Polyarteritis nodosa | 0 (0.0) | 1 (0.3) | 1.000 |
| Fuch’s iridocyclitis | 0 (0.0) | 1 (0.3) | 1.000 |
| Eales disease | 1 (0.8) | 0 (0.0) | 0.311 |
| Total | 134 (100.0) | 297 (100.0) | <0.001 |
Notes:
Fisher’s exact test on 2×2 table, eg, African American vs Caucasian compared on sarcoidosis vs all other diagnoses.
Fisher’s exact test applied to entire table, using Monte Carlo sampling.
Abbreviations: APMPPE, acute posterior multifocal placoid pigment epitheliopathy; CMV, cytomegaovirus; HLA, human leukocyte antigen; MEWDS, multiple evanescent white dot syndrome; seronegative SpA, seronegative spondyloarthropathy.
Multivariate analysis for race and sex
| Diagnosis | Odds ratio (95% confidence interval) | |
|---|---|---|
| Race | Sex | |
| Sarcoidosis | 6.54 [2.98, 15.29] | 0.89 [0.42, 1.91] |
| Anterior uveitis, undifferentiated | 1.58 [0.99, 2.51] | 1.02 [0.65, 1.60] |
| Herpetic anterior uveitis | 0.13 [0.02, 0.47] | 3.03 [1.32, 7.71] |
| Multifocal choroiditis | 1.24 [0.24, 5.52] | 0.11 [0.01, 0.68] |
| Trauma | 1.51 [0.83, 2.69] | 1.76 [0.97, 3.25] |
| Post-procedural | 1.14 [0.56, 2.24] | 0.55 [0.29, 1.06] |
Notes:
Odds ratios were computed via exact logistic regression. The odds ratios are >1 when African Americans or females are more likely to have the disease. The odds ratios are statistically significant if the 95% confidence interval does not include 1.
Figure 3Map of Virginia with the residential postal codes of the patients.
States of residence for patients seeking care at the University of Virginia
| State | Number of patients |
|---|---|
| AL | 1 |
| CA | 1 |
| FL | 2 |
| GA | 2 |
| MD | 3 |
| MI | 2 |
| NC | 1 |
| NM | 1 |
| NY | 1 |
| OR | 1 |
| SC | 2 |
| TN | 1 |
| VA | 462 |
| WA | 1 |
| WV | 7 |
| WY | 1 |
Abbreviations: AL, Alabama; CA, California; FL, Florida; GA, Georgia; MD, Maryland; MI, Michigan; NC, North Carolina; NM, New Mexico; NY, New York; OR, Oregon; SC, South Carolina; TN, Tennessee; VA, Virginia; WA, Washington; WV, West Virginia; WY, Wyoming.
Change in visual acuity
| Overall
| |||||
|---|---|---|---|---|---|
| Variable | N | Mean | SD | SE | Median |
| Initial logMAR | 458 | 0.54 | 0.74 | 0.03 | 0.3 |
| Final logMAR | 458 | 0.52 | 0.82 | 0.04 | 0.18 |
| Anterior uveitis | |||||
| Initial logMAR | 308 | 0.44 | 0.63 | 0.04 | 0.18 |
| Final logMAR | 308 | 0.45 | 0.78 | 0.04 | 0.16 |
| Intermediate uveitis | |||||
| Initial logMAR | 25 | 0.61 | 0.83 | 0.17 | 0.3 |
| Final logMAR | 25 | 0.27 | 0.35 | 0.07 | 0.14 |
| Posterior uveitis | |||||
| Initial logMAR | 64 | 1.07 | 1.05 | 0.13 | 0.63 |
| Final logMAR | 64 | 0.99 | 1.05 | 0.13 | 0.53 |
| Panuveitis | |||||
| Initial logMAR | 57 | 0.43 | 0.4 | 0.05 | 0.39 |
| Final logMAR | 57 | 0.45 | 0.63 | 0.08 | 0.25 |
Notes:
Wilcoxon rank sum test, analysis done at patient level.
Abbreviations: SD, standard deviation; SE, standard error of the mean.
Ophthalmic management and interventions
| Treatment/intervention | Number (%) |
|---|---|
| Local steroids | 365 (74.6%) |
| Systemic steroids | 133 (27.3%) |
| Anti-TNF agents | 17 (3.5%) |
| Antimetabolites | 52 (10.6%) |
| Intravitreal injection | 54 (11.0%) |
| Sub-Tenon injection | 23 (4.7%) |
| Glaucoma topical treatment | 116 (23.6%) |
| Glaucoma surgery | 43 (8.8%) |
| Cataract surgery | 129 (26.4%) |
| Pars plana vitrectomy | 46 (9.4%) |
Abbreviation: TNF, tumor necrosis factor.
Anatomical classification
| Definition | Number | Percentage | Number bilateral | Number unilateral |
|---|---|---|---|---|
| Anterior uveitis | 332 | 67.6 | 75 | 257 |
| Intermediate uveitis | 26 | 5.3 | 19 | 7 |
| Posterior uveitis | 62 | 12.6 | 32 | 30 |
| Panuveitis | 71 | 14.5 | 44 | 27 |
Figure 4Differentiated (diagnosed) vs undifferentiated (undiagnosed) cases.
Uveitis diagnoses at University of Virginia
| Diagnosis | Patients, n | Percentage |
|---|---|---|
| Anterior uveitis, undifferentiated | 126 | 25.7 |
| Trauma | 60 | 12.2 |
| Post-procedural | 49 | 10.0 |
| Viral | ||
| Acute retinal necrosis | 13 | 2.7 |
| Herpetic anterior uveitis | 39 | 7.9 |
| CMV uveitis | 4 | 0.8 |
| Herpetic panuveitis | 1 | 0.2 |
| Sarcoidosis | 33 | 6.7 |
| HLA-B27 anterior uveitis | 33 | 6.7 |
| Fuch’s iridocyclitis | 1 | 0.2 |
| Intermediate uveitis | 26 | 5.3 |
| Panuveitis, undifferentiated | 23 | 4.7 |
| Infectious | ||
| Toxoplasma | 14 | 2.9 |
| Syphilis | 1 | 0.2 |
| Tuberculosis | 1 | 0.2 |
| Fungal | 4 | 0.8 |
| Posterior uveitis, undifferentiated | 9 | 1.8 |
| White dot syndrome | ||
| Multifocal choroiditis | 9 | 1.8 |
| Birdshot | 7 | 1.4 |
| APMPPE | 4 | 0.8 |
| Serpiginous | 3 | 0.6 |
| MEWDS | 3 | 0.6 |
| Eales disease | 1 | 0.2 |
| Collagen vascular disease | ||
| Granulomatosis with polyangiitis | 1 | 0.2 |
| Polyarteritis nodosa | 1 | 0.2 |
| Seronegative SpA | ||
| Reactive arthritis | 1 | 0.2 |
| Ankylosing spondylitis | 5 | 1.0 |
| Crohn’s disease | 4 | 0.8 |
| Ulcerative colitis | 2 | 0.4 |
| Psoriatic arthritis | 1 | 0.2 |
| Others | 19 | 3.9 |
| Total | 491 | 100.0 |
Abbreviations: APMPPE, acute posterior multifocal placoid pigment epitheliopathy; CMV, cytomegalovirus; HLA, human leukocyte antigen; MEWDS, multiple evanescent white dot syndrome; seronegative SpA, seronegative spondyloarthropathy.
Multicenter comparison of anatomic location of uveitis
| UVA | Centers
| |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| United states
| International
| |||||||||
| MEEI | Duke | IA | UCLA | USC | KY | REH | SBU | UM | ||
| Time period | 1984–2014 | 1982–1992 | 1989–1994 | 1956–1960 | 1991–1994 | 2006–2007 | 1990–1995 | 1991–2013 | – | 2006–2010 |
| Patients (N) | 491 | 1,237 | 385 | 172 | 213 | 217,061 | 853 | 3,301 | 2,693 (ME) | 43 (FN) |
| Anterior uveitis (%) | 67.6 | 51.6 | 25 | 60.0 (I) | 90.6 (CBP) | 72 | 22.3 | 46 | 49.6 (ME) | 26.0 (FN) |
| Posterior uveitis (%) | 12.6 | 17.4 | 24 | 29 (I) | 4.7 (CBP) | 29 | 48.4 | 21.8 | 15.5 (ME) | 7.0 (FN) |
| Intermediate uveitis (%) | 5.3 | 13 | 12 | 6 | 1.4 (CBP) | 6 | 10.9 | 11.1 | 10.3 (ME) | 0.0 (FN) |
| Panuveitis (%) | 14.5 | 16 | 38 | 10.0 (I) | 1.4 (CBP) | 21 | 18.4 | 21.1 | 24.9 (ME) | 67.0 (FN) |
Notes:
IA and UCLA frequencies extrapolated from data, as different localization systems used.
Abbreviations: UVA, University of Virginia; MEEI, Massachusetts Eye and Ear Infirmary; Duke, Duke University; IA, University of Iowa; UCLA, University of California at Los Angeles; USC, University of Southern California; KY, University of Louisville, Kentucky; REH, The Royal Eye Hospital, Manchester, UK; SBU, Shahid Beheshti University of Medical Sciences, Tehran, Iran; UM, University of Manitoba, Winnipeg, Canada; ME, Middle East; EU, Europe; FN, First Nation; L, London; I, Iowa; CBP, Community Based Practice; URP, University Referral Practice.
Relative frequencies of key uveitis diagnoses
| UVA | Centers
| |||||||
|---|---|---|---|---|---|---|---|---|
| United States
| International
| |||||||
| MEEI | Duke | IA | UCLA | USC | KY | REH | ||
| (IA frequencies | (university referral frequencies | |||||||
| Time period | 1984–2014 | 1982–1992 | 1989–1994 | 1956–1960 | 1991–1994 | 2006–2007 | 1990–1995 | 1991–2013 |
| Patients, n | 491 | 1,237 | 385 | 172 | 213 | 217,061 | 853 | 3,301 |
| Sarcoidosis, % | 6.7 | 9.6 | 11 | 5 | 0.8 | 2 | 2.2 | 9.7 |
| Granulomatosis with polyangiitis, % | 0.2 | |||||||
| Polyarteritis nodosa, % | 0.2 | 0.2 | ||||||
| Anterior uveitis, undifferentiated, % | 25.7 | 37.8 | 12 | 60 | 30.5 | 54.2 | 7 | |
| Intermediate, % | 3.9 | 12 | 6 | 12.2 | 78.7 | |||
| Panuveitis, undifferentiated, % | 4.7 | 22.2 | 17 | 40 | 30.9 | 6.6 | ||
| Posterior uveitis, undifferentiated, % | 1.8 | 13.3 | 2 | 17 | 19.3 | |||
| Toxoplasma, % | 2.9 | 4.8 | 10 | 9 | 4 | 3.9 | 6.9 | |
| Syphilis, % | 0.2 | 1.7 | 0.5 | 1 | ||||
| Tuberculosis, % | 0.2 | 0.6 | 0.5 | 0.4 | ||||
| Fungal, % | 0.8 | 0.3 | ||||||
| Reactive arthritis, % | 0.2 | 1 | ||||||
| Ankylosing spondylitis, % | 1 | 3.8 | 2 | 3 | ||||
| Crohn’s disease, % | 0.8 | 0.7 | ||||||
| Ulcerative colitis, % | 0.4 | 0.5 | ||||||
| Psoriatic arthritis, % | 0.2 | |||||||
| Acute retinal necrosis, % | 2.7 | 2 | ||||||
| Herpetic anterior uveitis, % | 7.9 | 9.7 | 3 | |||||
| CMV uveitis, % | 0.8 | 2.2 | 15.1 | |||||
| Herpetic panuveitis, % | 0.2 | |||||||
| Multifocal choroiditis, % | 1.8 | 6 | 6.5 | 4.9 | ||||
| Birdshot, % | 1.4 | 0.78 | 6.5 | 1 | 1.6 | |||
| APMPPE, % | 0.8 | 0.5 | ||||||
| Serpiginous, % | 0.6 | 3.2 | 1.9 | |||||
| MEWDS, % | 0.6 | 0.4 | ||||||
| Trauma, % | 12.2 | |||||||
| Post-procedural, % | 10 | |||||||
| Fuch’s iridocyclitis, % | 0.2 | 2 | 1 | 11.5 | ||||
| Eales disease, % | 0.2 | |||||||
| Anterior uveitis HLA-B27, % | 6.7 | 31.3 | 19 | 17.8 | 8.4 | 3.6 | ||
| Others, % | 3.9 | |||||||
Notes:
IA and UCLA frequencies extrapolated from data, as different localization systems were used.
Abbreviations: APMPPE, acute posterior multifocal placoid pigment epitheliopathy; CMV, cytomegalovirus; Duke, Duke University; HLA, human leukocyte antigen; IA, University of Iowa; KY, University of Louisville, Kentucky; MEEI, Massachusetts Eye and Ear Infirmary; MEWDS, multiple evanescent white dot syndrome; REH, Royal Eye Hospital, Manchester, UK; UCLA, University of California at Los Angeles; USC, University of Southern California; UVA, University of Virginia.
Anterior uveitis diagnoses
| UVA | Duke | MEEI | USC | UCLA | KY | IA | REH | |
|---|---|---|---|---|---|---|---|---|
| Undifferentiated | 126 (38) | 49 | 37.8 | 12.1 | 50.5 | 54.2 | 60 | 12.3 |
| Trauma | 59 (17.8) | 0.8 | 2.7 | |||||
| Herpetic uveitis | 39 (11.7) | 3.0 | 9.7 | 9.0 | 2.2 | 1.7 | ||
| Post-procedural | 36 (10.5) | |||||||
| HLA-B27 | 33 (9.9) | 19.0 | 6.4 | 3.0 | 17.8 | 8.4 | 4.5 | |
| Sarcoidosis | 19 (5.7) | 3.0 | 5.8 | 1.2 | 11.0 | 2.39 | ||
| Ankylosing spondylitis | 4 (1.2) | 9.0 | 7.4 | 1.5 | 4.7 | 13.0 | ||
| IBD | 4 (1.2) | 1.0 | 2.4 | 0.7 | 7.0 | 0.96 | ||
| Reactive | 1 (0.3) | 3.0 | 4.0 | 1.0 | 12.0 | 0.66 | ||
| Psoriatic arthritis | 1 (0.3) | 0.8 | 0.57 | |||||
| Fuch’s heterochromic iridocyclitis | 1 (0.3) | 7.0 | 5.0 | 1.8 | 2.2 | 39.0 | 11.5 | |
| Granulomatosis with polyangiitis | 1 (0.3) | 0.5 | ||||||
| Others | 8 (2.7) |
Notes: Others included: TINU (3), rheumatoid arthritis (1), juvenile rheumatoid arthritis (1), multiple sclerosis (1), and Posner–Schlossman syndrome (2).
All values given as percentage only.
UCLA, IA, and REH values extrapolated from given data.
Abbreviations: Duke, Duke University; HLA, human leukocyte antigen; IA, University of Iowa; IBD, Inflammatory bowel disease; KY, University of Louisville, Kentucky; MEEI, Massachusetts Eye and Ear Infirmary; REH, Royal Eye Hospital, Manchester, UK; TINU, tubulointerstitial nephritis and uveitis; UCLA, University of California at Los Angeles; USC, University of Southern California; UVA, University of Virginia.
Intermediate uveitis diagnoses
| UVA | Duke | MEEI | USC | UCLA | KY | IA | REH | |
|---|---|---|---|---|---|---|---|---|
| Undifferentiated | 20 (77) | 98 | 69.1 | 100 | 30.8 | 94.7 | 40.0 | 7.8 |
| Sarcoidosis | 3 (11.5) | 2.0 | 22.2 | 0 | 1.75 | |||
| Multiple sclerosis | 2 (3.8) | 8.0 | 0 | 2.1 | 0.54 | |||
| Ankylosing spondylitis | 1 (3.8) |
Notes:
All values given as percentage only.
UCLA, IA, and REH values extrapolated from given data.
Abbreviations: Duke, Duke University; IA, University of Iowa; KY, University of Louisville, Kentucky; MEEI, Massachusetts Eye and Ear Infirmary; REH, Royal Eye Hospital, Manchester, UK; UCLA, University of California at Los Angeles; USC, University of Southern California; UVA, University of Virginia.
Posterior uveitis diagnoses
| UVA | Duke | MEEI | USC | UCLA | KY | IA | REH | |
|---|---|---|---|---|---|---|---|---|
| Toxoplasma | 11 (17.7) | 42.0 | 24.6 | 9.0 | 35.5 | 7.7 | 65.0 | 6.9 |
| Multifocal choroiditis | 9 (14.5) | 18.0 | 9.7 | 10.1 | 0.8 | |||
| Undifferentiated | 9 (14.5) | 9 | 13.3 | 15.0 | 16.2 | 19.3 | 48.0 | |
| Acute retinal necrosis | 4 (6.5) | 9 | 5.5 | 2.7 | 0.2 | |||
| Birdshot | 7 (11.3) | 3 | 7.9 | 3.0 | 6.5 | 3.4 | 1.09 | |
| MEWDS | 3 (4.8) | 1.25 | 1.2 | 0.4 | ||||
| APMPPE | 3 (4.8) | 2 | 2.0 | |||||
| Serpiginous | 3 (4.8) | 1.6 | 5.0 | 3.2 | 3.9 | 0.3 | ||
| Sarcoidosis | 2 (3.2) | 7.5 | 3.9 | 2.2 | 4.0 | 2.9 | ||
| CMV | 2 (3.2) | 11.6 | 7.0 | 31.2 | 0.7 | |||
| Syphilis | 1 (1.6) | 2.0 | 4.0 | |||||
| Polyarteritis nodosa | 1 (1.6) | 0.83 | ||||||
| Eales disease | 1 (1.6) | |||||||
| Others | 2 (3.2) |
Notes: Others included: IRVAN (2).
All values given as percentage only.
UCLA, IA, and REH values extrapolated from given data.
Abbreviations: APMPPE, acute posterior multifocal placoid pigment epitheliopathy; CMV, cytomegalovirus; Duke, Duke University; IA, University of Iowa; IRVAN, idiopathic retinitis, vasculitis, aneurysms, and neuroretinitis; KY, University of Louisville, Kentucky; MEEI, Massachusetts Eye and Ear Infirmary; MEWDS, multiple evanescent white dot syndrome; REH, Royal Eye Hospital, Manchester, UK; USC, University of Southern California; UCLA, University of California at Los Angeles; UVA, University of Virginia.
Panuveitis diagnoses
| UVA | Duke | MEEI | USC | UCLA | KY | IA | REH | |
|---|---|---|---|---|---|---|---|---|
| Undifferentiated | 23 (32.4) | 43.0 | 22.2 | 45.0 | 18.7 | 30.9 | 27.0 | |
| Post-procedural | 13 (18.3) | |||||||
| Acute retinal necrosis | 9 (12.7) | 18.0 | 1.3 | |||||
| Sarcoidosis | 9 (12.7) | 27.0 | 14.1 | 21.0 | 2.3 | 4.5 | 28.0 | 2.99 |
| Toxoplasma | 3 (4.2) | |||||||
| Fungal | 3 (4.2) | 2.0 | ||||||
| Herpetic uveitis | 2 (2.8) | 0.01 | ||||||
| Trauma | 1 (1.4) | |||||||
| Tuberculosis | 1 (1.4) | 1.0 | 2.0 | |||||
| Others | 4 (5.6) |
Notes: Others included: Behcet’s disease (1), Vogt–Koyanagi–Harada disease (1), juvenile rheumatoid arthritis (1).
All values given as percentage only.
UCLA, IA, and REH values extrapolated from given data.
Abbreviations: Duke, Duke University; IA, University of Iowa; KY, University of Louisville, Kentucky; MEEI, Massachusetts Eye and Ear Infirmary; REH, Royal Eye Hospital, Manchester, UK; UCLA, University of California at Los Angeles; USC, University of Southern California; UVA, University of Virginia.